Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: Analysis of SEER-medicare data

Jennifer M. Weiss, Jessica Schumacher, Glenn O. Allen, Heather Neuman, Erin O.Connor Lange, Noelle K. Loconte, Caprice C. Greenberg, Maureen A. Smith

Research output: Contribution to journalArticlepeer-review

37 Scopus citations

Abstract

Background: Survival benefit from adjuvant chemotherapy is established for stage III colon cancer; however, uncertainty exists for stage II patients. Tumor heterogeneity, specifically microsatellite instability (MSI), which is more common in right-sided cancers, may be the reason for this observation. We examined the relationship between adjuvant chemotherapy and overall 5-year mortality for stage II colon cancer by location (right- vs left-side) as a surrogate for MSI. Methods: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we identified Medicare beneficiaries from 1992 to 2005 with AJCC stage II (n = 23,578) and III (n = 17,148) primary adenocarcinoma of the colon who underwent surgery for curative intent. Overall 5-year mortality was examined with Kaplan-Meier survival analysis and Cox proportional hazards regression with propensity score weighting. Results: It was found that 18 % of stage II patients (n = 2941) with right-sided cancer and 22 % (n = 1693) with left-sided cancer received adjuvant chemotherapy. After adjustment, overall 5-year survival benefit from chemotherapy was observed only for stage III patients (right-sided: hazard ratio [HR], 0.64; 95 % CI, 0.59-0.68; p <.001 and left-sided: HR, 0.61; 95 % CI, 0.56-0.68; p <.001). No survival benefit was observed for stage II patients with either right-sided (HR, 0.97; 95 % CI, 0.87-1.09; p =.64) or left-sided cancer (HR, 0.97; 95 % CI, 0.84-1.12; p =.68). Conclusions: Among Medicare patients with stage II colon cancer, a substantial number receive adjuvant chemotherapy. Adjuvant chemotherapy did not improve overall 5-year survival for either right- or left-sided colon cancers. Our results reinforce existing guidelines and should be considered in treatment algorithms for older adults with stage II colon cancer.

Original languageEnglish (US)
Pages (from-to)1781-1791
Number of pages11
JournalAnnals of surgical oncology
Volume21
Issue number6
DOIs
StatePublished - Jun 2014
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint

Dive into the research topics of 'Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: Analysis of SEER-medicare data'. Together they form a unique fingerprint.

Cite this